Table 1 Characteristics of patients
Patient data | Intravesical chemotherapy drug | P | |
|---|---|---|---|
Gemcitabine (n = 84) n(%) | Epirubicin or Pirarubicin (n = 40) n(%) | ||
Gender | |||
Male | 61 (72.62%) | 30 (75%) | 0.779 |
Female | 23 (27.38%) | 10 (25%) | |
Age (years) | |||
< 65 | 39 (46.43%) | 14 (35%) | 0.229 |
≥ 65 | 45 (53.57%) | 26 (65%) | |
Multifocality | |||
Single | 41 (53.25%) | 20 (57.14%) | 0.701 |
Multiple | 36 (46.75%) | 15 (42.86%) | |
Size (cm) | |||
< 3 | 57 (67.86%) | 25 (62.5%) | 0.427 |
≥ 3 | 27 (32.14%) | 15 (37.5%) | |
Grade | |||
Low | 42 (57.53%) | 19 (51.35%) | 0.538 |
High | 31 (42.47%) | 18 (48.65%) | |
Risk | |||
Low | 19 (22.62%) | 13 (32.50%) | 0.452 |
Immediate | 25 (29.76%) | 9 (22.50%) | |
High | 40 (47.62%) | 18 (45.00%) | |
reTURBT | |||
Yes | 33 (39.29%) | 17 (42.50%) | 0.733 |
No | 51 (60.71%) | 23 (57.50%) | |
Follow up months | |||
(mean ± SD) | 34.8 (17.9) | 35.9 (22.1) | 0.772 |